Laurus Labs Q2 FY27 Revenue ₹2,206 Cr, Profit ₹441 Cr
Laurus Labs announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The company reported a significant increase in revenue and profits, with Q2 FY27 revenue at ₹2,206 Crore (up 33% YoY) and net profit at ₹441 Crore (up 126% YoY). For H1 FY27, revenue stood at ₹4,233 Crore (up 31% YoY) and net profit at ₹809 Crore (up 126% YoY). EBITDA also saw substantial growth, reaching ₹762 Crore in Q2 FY27 and ₹1,406 Crore in H1 FY27. The company highlighted strong performance in its CDMO segment, particularly in small molecules, and also announced investments in Oligonucleotides and peptide-resins technologies to enhance its integrated CDMO offering. Additionally, Laurus Labs declared an interim dividend of ₹1.00 per share.
Key Highlights
- Q2 FY27 revenue surged 33% YoY to ₹2,206 Cr.
- Net profit in Q2 FY27 grew 126% YoY to ₹441 Cr.
- H1 FY27 revenue increased 31% YoY to ₹4,233 Cr.
- CDMO segment showed strong growth, especially in small molecules.
- Interim dividend of ₹1.00 per share declared.
Price Impact
More from LAURUSLABS